EE03515B1 - GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis - Google Patents

GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis

Info

Publication number
EE03515B1
EE03515B1 EE9700208A EE9700208A EE03515B1 EE 03515 B1 EE03515 B1 EE 03515B1 EE 9700208 A EE9700208 A EE 9700208A EE 9700208 A EE9700208 A EE 9700208A EE 03515 B1 EE03515 B1 EE 03515B1
Authority
EE
Estonia
Prior art keywords
treatment
gnrh antagonist
dependent condition
steroid dependent
gonadal steroid
Prior art date
Application number
EE9700208A
Other languages
English (en)
Estonian (et)
Other versions
EE9700208A (et
Inventor
D. Hodgen Gary
Philips Audrey
Original Assignee
The Medical College Of Hampton Roads
Ortho Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03515(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by The Medical College Of Hampton Roads, Ortho Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads
Publication of EE9700208A publication Critical patent/EE9700208A/xx
Publication of EE03515B1 publication Critical patent/EE03515B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
EE9700208A 1994-07-22 1995-07-18 GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis EE03515B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
EE9700208A EE9700208A (et) 1998-02-16
EE03515B1 true EE03515B1 (et) 2001-10-15

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700208A EE03515B1 (et) 1994-07-22 1995-07-18 GnRH antagonist kasutamiseks gonadaalsteroid-sõltuva seisundi ravis

Country Status (29)

Country Link
EP (1) EP0769956B1 (de)
JP (1) JP3138477B2 (de)
CN (1) CN1137722C (de)
AP (1) AP775A (de)
AT (1) ATE190494T1 (de)
AU (1) AU691952B2 (de)
BG (1) BG63363B1 (de)
BR (1) BR9508718A (de)
CA (1) CA2195745C (de)
CY (1) CY2228B1 (de)
CZ (1) CZ291803B6 (de)
DE (1) DE69515666T2 (de)
DK (1) DK0769956T3 (de)
EE (1) EE03515B1 (de)
ES (1) ES2145286T3 (de)
FI (1) FI970244L (de)
GR (1) GR3033590T3 (de)
HU (1) HU218910B (de)
IL (1) IL114655A (de)
IS (1) IS4413A (de)
LV (1) LV11823B (de)
MX (1) MX9700574A (de)
NO (1) NO970257L (de)
NZ (1) NZ290554A (de)
OA (1) OA10730A (de)
PT (1) PT769956E (de)
RU (1) RU2181598C2 (de)
SK (1) SK282118B6 (de)
WO (1) WO1996003138A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
NZ534836A (en) * 1999-09-23 2007-07-27 Zentaris Gmbh Method for the therapeutic management of extrauterine proliferatoin of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (de) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen
EP2307040B1 (de) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Gnrh und sexhormone zur behandlung von viruserkrankungen, insbesondere hiv/aids
HUE047732T2 (hu) * 2015-05-18 2020-05-28 Nerre Therapeutics Ltd NK-1/NK-3 receptor antagonista vértolulások kezeléséhez
PL3765024T3 (pl) 2018-03-14 2024-08-05 KaNDy Therapeutics Limited <div>Nowa formulacja farmaceutyczna zawierająca podwójnych antagonistów receptora nk-1/nk-3</div>
EP3560555A1 (de) * 2018-04-26 2019-10-30 LifeArc Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CN1200674A (zh) 1998-12-02
NO970257D0 (no) 1997-01-21
HU218910B (hu) 2000-12-28
NO970257L (no) 1997-01-21
JP3138477B2 (ja) 2001-02-26
JPH10503203A (ja) 1998-03-24
IL114655A0 (en) 1995-11-27
NZ290554A (en) 2000-08-25
PT769956E (pt) 2000-07-31
LV11823A (lv) 1997-08-20
AP775A (en) 1999-10-28
CZ291803B6 (cs) 2003-06-18
CY2228B1 (en) 2003-04-18
CZ15097A3 (en) 1997-11-12
FI970244A7 (fi) 1997-01-21
LV11823B (en) 1998-03-20
FI970244A0 (fi) 1997-01-21
IS4413A (is) 1997-01-14
CN1137722C (zh) 2004-02-11
HU9700046D0 (en) 1997-02-28
AP9700913A0 (en) 1997-01-31
MX9700574A (es) 1997-12-31
WO1996003138A1 (en) 1996-02-08
SK7097A3 (en) 1997-11-05
AU691952B2 (en) 1998-05-28
RU2181598C2 (ru) 2002-04-27
EP0769956A4 (de) 1999-03-10
GR3033590T3 (en) 2000-09-29
CA2195745A1 (en) 1996-02-08
IL114655A (en) 2005-08-31
EP0769956B1 (de) 2000-03-15
OA10730A (en) 2001-06-07
EE9700208A (et) 1998-02-16
ATE190494T1 (de) 2000-04-15
BG101158A (bg) 1997-09-30
AU3132095A (en) 1996-02-22
EP0769956A1 (de) 1997-05-02
DE69515666T2 (de) 2000-07-06
SK282118B6 (sk) 2001-11-06
ES2145286T3 (es) 2000-07-01
HUT77127A (hu) 1998-03-02
CA2195745C (en) 2005-03-29
DK0769956T3 (da) 2000-06-05
BR9508718A (pt) 1997-12-30
BG63363B1 (bg) 2001-11-30
FI970244L (fi) 1997-01-21
DE69515666D1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
IS4478A (is) Tæki sem sýnir skammta
HU9602550D0 (en) Gnrh antagonists
BR9509997A (pt) Antagonista de taquiquinina
DE69432921D1 (de) Schnittstelleneinrichtung
DE69517385D1 (de) Diebstahlverhütungseinrichtung
DE69501586D1 (de) Abgabevorrichtung
PT778023E (pt) Agentes neuroprotectores
DE69529449D1 (de) Brennstoffbehandlungsvorrichtung
DE69513993D1 (de) Abschaltvorrichtung
UA22440C2 (uk) Пристрій для hатягуваhhя hитки
DE69509966D1 (de) Badevorrichtung
DE59711085D1 (de) Therapiegerät
DE59710593D1 (de) Therapiegerät
IL114655A (en) USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
DE69526175D1 (de) Behandlungsgerät
AP2000001743A0 (en) Dosage device
GB2289422B (en) Bowls practice device
DE69516439D1 (de) Behandlungsgerät
ATA218894A (de) Physikotherapeutische behandlungsvorrichtung
KR950027351U (ko) 반목 항타장치
KR960004797U (ko) 자동차의 도난 방지 장치
PT914233E (pt) Dispositivo de dosagem
KR950029464U (ko) 자력 발생 욕조기
KR960006324U (ko) 프로빙 시간단축 쏘소자
FI955850L (fi) Lukittava laitekotelo

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100718